2',3'-dideoxyguanosine

RN provided by first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Hepatoblastoma 11/01/1991 - "Hep G2-derived hepatoblastoma cells (2.2.15), which actively produce hepatitis B virus (HBV), were cultured in the presence of 2',3'-dideoxyguanosine (ddG), 2',3'-dideoxyinosine, or 3'-azido-2',3'-dideoxythymidine (AZT). "
2.	Infections 12/01/2018 - "2',3'-dideoxyguanosine (DoG) has been demonstrated to inhibit duck hepatitis B virus (DHBV) replication in vivo in a duck model of HBV infection. "
3.	AIDS-Related Complex (ARC) 01/01/1991 - "Since DNA polymerase beta plays a role in DNA repair, the present results predict possible appearance of cytotoxicity or clinical side effect(s) of 2',3'-dideoxyguanosine (ddG), known as a potent inhibitor of human immunodeficiency virus, when ddG is administered to the patients with acquired immune deficiency syndrome (AIDS) or AIDS-related complex."
4.	Acquired Immunodeficiency Syndrome (AIDS) 01/01/1991 - "Since DNA polymerase beta plays a role in DNA repair, the present results predict possible appearance of cytotoxicity or clinical side effect(s) of 2',3'-dideoxyguanosine (ddG), known as a potent inhibitor of human immunodeficiency virus, when ddG is administered to the patients with acquired immune deficiency syndrome (AIDS) or AIDS-related complex."

1.	DNA Polymerase beta (DNA Polymerase IV)
2.	Didanosine (Videx)
3.	Zidovudine (Retrovir)